EVO:NSD-Evotec SE ADR (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 4.73

Change

0.00 (0.00)%

Market Cap

USD 1.68B

Volume

0.53M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, fibrosis, immunology, pain and inflammation, infectious, kidney, liver, rare, respiratory, fibrotic and metabolic disease; central nervous system (CNS) and cardio metabolic disorders; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. It also has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB; Bayer, Novo Nordisk, Eli Lilly, and Novartis company for kidney disease; and Sandoz, patient advocacy groups, and venture capital, as well as a strategic research collaboration agreement with Bristol Myers Squibb to build a molecular glue based pipeline for unmet medical needs. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-24 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
UTHR United Therapeutics Corporatio..

N/A

USD 13.60B
NBIX Neurocrine Biosciences Inc

N/A

USD 11.63B
VTRS Viatris Inc

N/A

USD 9.73B
LNTH Lantheus Holdings Inc

N/A

USD 7.11B
ALKS Alkermes Plc

N/A

USD 4.74B
ALVO Alvotech

N/A

USD 2.92B
HCM HUTCHMED DRC

N/A

USD 2.57B
BCRX BioCryst Pharmaceuticals Inc

N/A

USD 2.09B
KNSA Kiniksa Pharmaceuticals Ltd

N/A

USD 1.92B
SUPN Supernus Pharmaceuticals Inc

N/A

USD 1.80B

ETFs Containing EVO

EXV9:XETRA iShares (DE) I - iShares .. 12.11 % 0.00 %

N/A

USD 0.10B
BETS:XETRA 6.59 % 0.00 %

N/A

N/A
ODDS Pacer BlueStar Digital En.. 6.28 % 0.00 %

N/A

USD 1.71M
XWD1:LSE Xtrackers MSCI World Swap.. 1.75 % 0.00 %

N/A

N/A
BJK VanEck Gaming ETF 0.00 % 0.66 %

N/A

N/A
EWD iShares MSCI Sweden ETF 0.00 % 0.53 %

N/A

N/A
IESZ:LSE 0.00 % 0.00 %

N/A

N/A
OMXS:LSE iShares OMX Stockholm Cap.. 0.00 % 0.00 %

N/A

N/A
ITEK:LSE HAN-GINS Tech Megatrend E.. 0.00 % 0.00 %

N/A

USD 0.09B
DXSN:F Xtrackers - ShortDAX Dail.. 0.00 % 0.00 %

N/A

N/A
DXSP:F Xtrackers - Euro Stoxx 50.. 0.00 % 0.00 %

N/A

N/A
EL4C:F Deka STOXX Europe Strong .. 0.00 % 0.00 %

N/A

N/A
EXV9:F 0.00 % 0.00 %

N/A

N/A
XDN0:F db x-trackers MSCI Nordic.. 0.00 % 0.00 %

N/A

USD 1.06B
OM3X:XETRA iShares OMX Stockholm Cap.. 0.00 % 0.00 %

N/A

N/A
XDN0:XETRA db x-trackers MSCI Nordic.. 0.00 % 0.00 %

N/A

N/A
DXW:CA Dynamic Active Internatio.. 0.00 % 0.00 %

N/A

CAD 0.02B
ITEP:LSE HAN-GINS Tech Megatrend E.. 0.00 % 0.00 %

N/A

USD 0.09B
BETZ Roundhill Sports Betting .. 0.00 % 0.00 %

N/A

USD 0.07B
XNZN:XETRA Xtrackers Nordic Net Zero.. 0.00 % 0.00 %

N/A

N/A
XDN0:SW Xtrackers MSCI Nordic UCI.. 0.00 % 0.00 %

N/A

USD 1.14B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.70% 73% C 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.70% 73% C 83% B
Trailing 12 Months  
Capital Gain -0.84% 70% C- 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.84% 70% C- 50% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -23.11% 17% F 12% F
Dividend Return -23.11% 17% F 12% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.56% 86% B+ 63% D
Risk Adjusted Return -83.84% 12% F 7% C-
Market Capitalization 1.68B 85% B 78% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector